43 patents
Page 2 of 3
Utility
Antisense Nucleic Acids
17 Feb 22
Provided is a drug that allows highly-efficient skipping of exon.
Naoki WATANABE, Yuuichirou TONE, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 2 Nov 21
Utility
1,3,4-OXADIAZOLONE Compound and Pharmaceutical
27 Jan 22
Hirotaka KAMITANI, Hisaaki ZAIMOKU, Yoshinari HARUTA, Takeo KIKUCHI
Filed: 14 Nov 19
Utility
me8os3molu8y szwdspg
2 Dec 21
The purpose of the present invention is to provide compounds having an M3 PAM action.
Kouya OIKAWA, Sho HIRAI, Kazuhiko WAKITA, Akiko FUJIBAYASHI
Filed: 7 May 19
Utility
js7ccu51o6kgfum0jt56nrock3wwvx34jsmne7rg2yzt3b9t1b1 o4urwe2
4 Nov 21
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 14 Jul 21
Utility
u80wmqlmee7en1h4io2ifzhxv66i5
16 Sep 21
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 28 May 21
Utility
dntefh4tdr0hxu4q5foqp3fdzji0hwd5k8 p60ir
26 Aug 21
Yutaro KOTOBUKI, Fumiya URABE
Filed: 10 May 19
Utility
7znvgt9s7g7npqz7xhyh1sj381eol
26 Aug 21
The present invention relates to a composition containing an antisense oligonucleotide, and the use thereof to treat Duchenne muscular dystrophy.
Tomonori UNO, Takashi NATSUKAWA, Youichi EGAWA, Youhei SATOU
Filed: 26 Jun 19
Utility
iohwp99lvov7arz 49la9fde46co82vojl
22 Jul 21
Naoki WATANABE, Haruna SEO, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 21 Aug 20
Utility
2565loq4 20jmvapevsn8gcgmoj34wvpv0s6id4a6j17a7y3bs
1 Jul 21
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 12 Feb 21
Utility
m0rvp9osrgfb904hk6e kkrj
17 Jun 21
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 18 Dec 20
Utility
t9i4 8kesarwlq2e100h
20 May 21
The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
Yukiko ENYA, Yuichiro TONE, Shin'ichi TAKEDA, Yoshitsugu AOKI
Filed: 17 Nov 20
Utility
6btiso1h32n197dyxh55t3m7
22 Apr 21
Toshio FUJIWARA
Filed: 28 Dec 20
Utility
92jyhxghrqj71apjqwcs021i35z578hewhbq4mx6pak
21 Jan 21
Fumi HIGUCHI
Filed: 29 Sep 20
Utility
3otskbezrowdlf0ghv16t
23 Dec 20
Toshinori TANAKA, Rie YAMADA
Filed: 19 Feb 19
Utility
m1cb71vnihvzhr71apesphs55l1u6bsq73wrjd7luxnl23wwlq
18 Nov 20
Shouji FURUTA, Naoto HATTORI
Filed: 14 Nov 18
Utility
jucgd1hop1uy6ax63td0nvao
15 Jul 20
Toshio FUJIWARA
Filed: 26 Sep 18
Utility
8ie7 n7d6z7v5ah2x50pvx
15 Jul 20
A main object of the present invention is to provide new crystals of (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine maleate (hereinafter, referred to as “compound A”).
Toshio FUJIWARA, Joanna BIS, Senthil Kumar Kusalakumari SUKUMAR
Filed: 26 Sep 18
Utility
cbmpwuvcj41u2kckm5eh5 ti40qjlc7nrmgmhg2
13 May 20
Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene.
Tatsushi WAKAYAMA, Haruna SEO, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 10 Jun 19
Utility
suqdcbcz4zph7pidnb7xq0p74ak bdz0juj96sj0
22 Apr 20
There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level.
Shinichiro NAKAGAWA
Filed: 19 Dec 19
Utility
dg3jrh5r5qrpsxyfz6gmypgdbcmbt0m28z7fu
15 Apr 20
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 9 May 19